Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: Bob L who wrote (1525)	4/9/1998 9:31:00 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 1762

Thanks for the statistical boost BobL, Meanwhile, over on the Techniclone discussion on Yahoo, this was said: "No siree Bio! Rituxan and Bexxar kill all the B cells and leave the treated person vulnerable to anything until the body can rebuild the B cells. "Oncolym attacks the cancerous cells almost exclusively. Lym 2 will do the same but without radiation. Rituxan may not even be the treatment of choice after Bexxar and Oncolym hit the market. Rituxan has Genentech and Roche. Who will market Bexxar and Oncolym? They all are effective but to varying degrees. I'm sure the pharmaceuticals know and the door is open to better treatments. " It seems to me that IDEC are in a competitive situation with Techniclone which is in financial and management difficulties. Although Techniclone has good technology. The logical outcome seems to be that IDEC buy Techniclone, which would give IDEC a wider lymphoma treatment portfolio, get the treatment to patients faster, maximize value and profits and overall be a good thing. Techniclone is a bargain basement ~$20 million market capitalisation and badly needing funds at present. What do you say IDEC? As a shareholder of Techniclone, you are welcome to my shares and more of my money if you issue more shares. Maurice